Clynes, M. A.
,
Westbury, L. D.
Dennison, E. M.
Kanis, J. A.
Javaid, M. K.
Harvey, N. C.
Fujita, M.
Cooper, C.
Leslie, W. D.
Shuhart, C. R.
Funding for this research was provided by:
International Society for Clinical Densitometry
International Osteoporosis Foundation
UK Medical Research Council
University of Southampton
Article History
Received: 6 March 2020
Accepted: 22 April 2020
First Online: 6 May 2020
Compliance with ethical standards
:
: MAC reports personal fees (outside the submitted work) from UCB, Pfizer, and Eli Lilly for conference attendance; CC reports personal fees (outside the submitted work) from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestle, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. EMD reports personal fees (outside the submitted work) from Pfizer Healthcare and from the UCB Discussion panel. NCH reports consultancy, lecture fees and honoraria (outside the submitted work) from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma. JAK reports grants (outside the submitted work) from Radius Health, Amgen and UCB. CRS reports Consultant for Amgen and President of the International Society for Clinical Densitometry (2019–2020). All other authors declare that they have no conflicts of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.